Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank-Reference-Cited by-同舟云学术

Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank

Published:2022-03-04 Issue:3 Volume:5 Page:
ISSN:2398-9238
Container-title:Endocrinology, Diabetes & Metabolism
language:en
Short-container-title:Endocrino Diabet & Metabol

Author:

English Andrew R.¹^ORCID,Prasad Bodhayan¹^ORCID,McGuigan Declan H.¹,Horigan Geraldine¹^ORCID,O’Kane Maurice²³,Bjourson Anthony J.¹,Shukla Priyank¹,Kelly Catriona¹,McClean Paula L.¹

Affiliation:

1. Northern Ireland Centre for Stratified Medicine School of Biomedical Sciences C‐TRIC Altnagelvin Hospital Ulster University Derry~Londonderry UK

2. Clinical Chemistry Laboratory Altnagelvin Hospital Derry~Londonderry UK

3. Centre for Personalised Medicine: Clinical Decision Making and Patient Safety C‐TRIC Altnagelvin Hospital Londonderry UK

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/edm2.326

Reference33 articles.

1. Statin therapy prescribing for patients with type 2 diabetes mellitus: a review of current evidence and challenges;Elnaem MH;J Pharm Bioallied Sci,2017

2. National Institute for Health and Care Excellence.Cardiovascular disease: risk assessment and reduction including lipid modification.2017. NICE. Accessed 9/7/2017 https://www.nice.org.uk/guidance/cg181

3. Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease

4. Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis

5. Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study